Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYT004-MelQbG10 + imiquimod
- Development stage
- Unknown
- Lead developer
- Kuros Biosciences
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Topical
01
Overview
CYT004-MelQbG10 + imiquimod is a combination therapy under investigation for the treatment of melanoma and potentially other cancers. CYT004-MelQbG10 is a virus-like particle-based vaccine targeting the melanoma antigen Melan-A/MART-1, designed to stimulate an immune response against melanoma cells. Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist, used topically to treat actinic keratosis, superficial basal cell carcinoma, and genital/perianal warts. In this combination, imiquimod serves as an adjuvant to enhance local immune activation at the site of vaccine administration by inducing proinflammatory cytokines and activating antigen-presenting cells[4][6][8]. The overall mechanism aims to boost both innate and adaptive anti-tumor immunity.
- Other names
- CYT004-MelQbG10CYT-004-MelQbG10CYT 004-MelQbG10
02
Targets
TLR9 (Toll-like receptor 9)MLANA (Melanoma antigen recognized by T cells 1)TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on CYT004-MelQbG10 + imiquimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYT004-MelQbG10 + imiquimod.